CNN reports on the neglected health burden of Chagas disease and its significant increase for risk of death.
In an exclusive interview with PharmaVOICE's Editor Taren Grom, Cameron Durrant, M.D., current CEO and chairman of KaloBios, talks about taking the helm of the embattled small biotech company amid ...
It was a nice thing — and a great PR move — when Allergan plc CEO Brent Saunders earlier this month blogged about his responsible pricing pledge. Cameron Durrant’s been there, done that. Five months ...
KaloBios Pharmaceuticals, Inc. (OTC:KBIOQ), a developmental stage biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has emerged from Chapter 11 bankruptcy ...
By Kamran Rafiq
In this exclusive International Society for Neglected Tropical Diseases (ISNTD) interview, Dr. Durrant talks about the adoption of a new pricing model that will guide ...
By Danny Levine
In April, the development-stage company unveiled a pricing plan based on transparency, affordability, and reasonable profit. We spoke to Cameron Durrant, CEO of KaloBios, about ...